6 results on '"didier CARRIE"'
Search Results
2. Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes
- Author
-
Michael E. Farkouh, Michael Domanski, George D. Dangas, Lucas C. Godoy, Michael J. Mack, Flora S. Siami, Taye H. Hamza, Binita Shah, Giulio G. Stefanini, Mandeep S. Sidhu, Jean-François Tanguay, Krishnan Ramanathan, Samin K. Sharma, John French, Whady Hueb, David J. Cohen, Valentin Fuster, Tanim N. Zazif, Hoang Thai, Jeffrey R Burton, Erick Schampaert, Jorge Escobedo, Jean-Luc Dubois-Rande, Carlos Macaya, Didier Carrie, Gert Richardt, Ariel Roguin, Chaim Lotan, Ran Kornowski, Patrizia Presbitero, J. Eduardo Sousa, Jorge G. Velásquez, Alfredo Rodriguez, Gerry Devlin, John K. French, and Upendra Kaul
- Subjects
medicine.medical_specialty ,Proportional hazards model ,business.industry ,medicine.medical_treatment ,Mortality rate ,Hazard ratio ,Percutaneous coronary intervention ,030204 cardiovascular system & hematology ,Revascularization ,medicine.disease ,Coronary artery disease ,03 medical and health sciences ,surgical procedures, operative ,0302 clinical medicine ,Internal medicine ,Cohort ,Conventional PCI ,medicine ,Cardiology ,cardiovascular diseases ,030212 general & internal medicine ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background The FREEDOM (Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease) trial demonstrated that for patients with diabetes mellitus (DM) and multivessel coronary disease (MVD), coronary artery bypass grafting (CABG) is superior to percutaneous coronary intervention with drug-eluting stents (PCI-DES) in reducing the rate of major adverse cardiovascular and cerebrovascular events after a median follow-up of 3.8 years. It is not known, however, whether CABG confers a survival benefit after an extended follow-up period. Objectives The purpose of this study was to evaluate the long-term survival of DM patients with MVD undergoing coronary revascularization in the FREEDOM trial. Methods The FREEDOM trial randomized 1,900 patients with DM and MVD to undergo either PCI with sirolimus-eluting or paclitaxel-eluting stents or CABG on a background of optimal medical therapy. After completion of the trial, enrolling centers and patients were invited to participate in the FREEDOM Follow-On study. Survival was evaluated using Kaplan-Meier analysis, and Cox proportional hazards models were used for subgroup and multivariate analyses. Results A total of 25 centers (of 140 original centers) agreed to participate in the FREEDOM Follow-On study and contributed a total of 943 patients (49.6% of the original cohort) with a median follow-up of 7.5 years (range 0 to 13.2 years). Of the 1,900 patients, there were 314 deaths during the entire follow-up period (204 deaths in the original trial and 110 deaths in the FREEDOM Follow-On). The all-cause mortality rate was significantly higher in the PCI-DES group than in the CABG group (24.3% [159 deaths] vs. 18.3% [112 deaths]; hazard ratio: 1.36; 95% confidence interval: 1.07 to 1.74; p = 0.01). Of the 943 patients with extended follow-up, the all-cause mortality rate was 23.7% (99 deaths) in the PCI-DES group and 18.7% (72 deaths) in the CABG group (hazard ratio: 1.32; 95% confidence interval: 0.97 to 1.78; p = 0.076). Conclusions In patients with DM and MVD, coronary revascularization with CABG leads to lower all-cause mortality than with PCI-DES in long-term follow-up. (Comparison of Two Treatments for Multivessel Coronary Artery Disease in Individuals With Diabetes [FREEDOM]; NCT00086450)
- Published
- 2019
3. TCT-474 FANTOM II Long Lesion Study: Initial Safety and Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions—First Report: 2-Year Outcomes
- Author
-
Matthias Lutz, Bernard Chevalier, Didier Carrie, Jeffrey Anderson, and Alexandre Abizaid
- Subjects
Scaffold ,medicine.medical_specialty ,business.industry ,Lesion study ,Fantom ,Sirolimus ,Medicine ,Radiology ,Cardiology and Cardiovascular Medicine ,business ,Long lesions ,computer ,medicine.drug ,computer.programming_language - Published
- 2021
4. Late Outcomes of Transcatheter Aortic Valve Replacement in High-Risk Patients
- Author
-
Martine Gilard, Hélène Eltchaninoff, Patrick Donzeau-Gouge, Karine Chevreul, Jean Fajadet, Pascal Leprince, Alain Leguerrier, Michel Lievre, Alain Prat, Emmanuel Teiger, Thierry Lefevre, Didier Tchetche, Didier Carrié, Dominique Himbert, Bernard Albat, Alain Cribier, Arnaud Sudre, Didier Blanchard, Gilles Rioufol, Frederic Collet, Remi Houel, Pierre Dos Santos, Nicolas Meneveau, Said Ghostine, Thibaut Manigold, Philippe Guyon, Dominique Grisoli, Herve Le Breton, Stephane Delpine, Romain Didier, Xavier Favereau, Geraud Souteyrand, Patrick Ohlmann, Vincent Doisy, Gilles Grollier, Antoine Gommeaux, Jean-Philippe Claudel, Francois Bourlon, Bernard Bertrand, Marc Laskar, Bernard Iung, Michel Bertrand, Jean Cassagne, Jacques Boschat, Jean Rene Lusson, Pierre Mathieu, Yves Logeais, Jean-Paul Bessou, Bernard Chevalier, Arnaud Farge, Philippe Garot, Thomas Hovasse, Marie Claude Morice, Mauro Romano, Patrick Donzeau Gouge, Olivier Vahdat, Bruno Farah, Didier Carrie, Nicolas Dumonteil, Gérard Fournial, Bertrand Marcheix, Patrick Nataf, Alec Vahanian, Florence Leclercq, Christophe Piot, Laurent Schmutz, Pierre Aubas, A. du Cailar, A. Dubar, N. Durrleman, F. Fargosz, Gilles Levy, Eric Maupas, François Rivalland, G. Robert, Christophe Tron, Francis Juthier, Thomas Modine, Eric Van Belle, Carlo Banfi, Thierry Sallerin, Olivier Bar, Christophe Barbey, Stephan Chassaing, Didier Chatel, Olivier Le Page, Arnaud Tauran, Daniele Cao, Raphael Dauphin, Guy Durand de Gevigney, Gérard Finet, Olivier Jegaden, Jean-François Obadia, Farzin Beygui, Jean-Philippe Collet, Alain Pavie, Frédéric Collet, null Pecheux, null Bayet, Alain Vaillant, Jacques Vicat, Olivier Wittenberg, Rémi Houel, Patrick Joly, Roger Rosario, Patrice Bergeron, Jacques Bille, Richard Gelisse, Jean-Paul Couetil, Jean-Luc Dubois Rande, Delphine Hayat, Emilie Fougeres, Jean-Luc Monin, Gauthier Mouillet, Florence Arsac, Emmanuel Choukroun, Marina Dijos, Jean-Philippe Guibaud, Lionel Leroux, Nicolas Elia, null Descotes Genon, Sidney Chocron, François Schiele, Christophe Caussin, Alexandre Azmoun, Saïd Ghostine, Rémi Nottin, Ashok Tirouvanziam, Dominique Crochet, Régis Gaudin, Jean-Christian Roussel, Nicolas Bonnet, Franck Digne, Patrick Mesnidrey, Thierry Royer, Victor Stratiev, Jean-Louis Bonnet, Thomas Cuisset, Hervé Le Breton, Issal Abouliatim, Marc Bedossa, Dominique Boulmier, Jean Philippe Verhoye, Stéphane Delepine, Jean-Louis Debrux, Alain Furber, Frédéric Pinaud, Eric Bezon, Jean-Noel Choplain, Oliver Bical, Grégoire Dambrin, Philippe Deleuze, Arnaud Jegou, Jean-René Lusson, Kasra Azarnouch, Nicolas Durel, Andrea Innorta, Géraud Souteyrand, Yves Lienhart, Ricardo Roriz, Patrick Staat, Jean-Noël Fabiani, Antoine Lafont, Rachid Zegdi, Didier Heudes, Michel Kindo, Jean-Philippe Mazzucotelli, Michel Zupan, Calin Ivascau, Thérèse Lognone, Massimo Massetti, Rémy Sabatier, Bruno Huret, Philippe Hochart, Damien Bouchayer, François Gabrielle, Franck Pelissier, Guillaume Tremeau, François Bourlon, Gilles Dreyfus, Armand Eker, Yakoub Habib, Nicolas Hugues, Claude Mialhe, Olivier Chavanon, Paolo Porcu, and Gérald Vanzetto
- Subjects
medicine.medical_specialty ,Framingham Risk Score ,Transcatheter aortic ,business.industry ,Incidence (epidemiology) ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,medicine.disease ,3. Good health ,Surgery ,03 medical and health sciences ,Stenosis ,0302 clinical medicine ,Valve replacement ,Aortic valve stenosis ,medicine ,030212 general & internal medicine ,Cardiology and Cardiovascular Medicine ,Risk assessment ,business ,Prospective cohort study - Abstract
BACKGROUND Transcatheter aortic valve replacement (TAVR) has revolutionized management of high-risk patients with severe aortic stenosis. However, survival and the incidence of severe complications have been assessed in relatively small populations and/or with limited follow-up. OBJECTIVES This report details late clinical outcome and its determinants in the FRANCE-2 (FRench Aortic National CoreValve and Edwards) registry. METHODS The FRANCE-2 registry prospectively included all TAVRs performed in France. Follow-up was scheduled at 30 days, at 6 months, and annually from 1 to 5 years. Standardized VARC (Valve Academic Research Consortium) outcome definitions were used. RESULTS A total of 4,201 patients were enrolled between January 2010 and January 2012 in 34 centers. Approaches were transarterial (transfemoral 73%, transapical 18%, subclavian 6%, and transaortic or transcarotid 3%) or, in 18% of patients, transapical. Median follow-up was 3.8 years. Vital status was available for 97.2% of patients at 3 years. The 3-year all-cause mortality was 42.0% and cardiovascular mortality was 17.5%. In a multivariate model, predictors of 3-year all-cause mortality were male sex (p = 2 of 4 (p < 0.001). Severe events according to VARC criteria occurred mainly during the first month and subsequently in < 2% of patients/year. Mean gradient, valve area, and residual aortic regurgitation were stable during follow-up. CONCLUSIONS The FRANCE-2 registry represents the largest database available on late results of TAVR. Late mortality is largely related to noncardiac causes. Incidence rates of severe events are low after the first month. Valve performance remains stable over time. (J Am Coll Cardiol 2016; 68: 1637-47) (C) 2016 by the American College of Cardiology Foundation.
- Published
- 2016
5. TCT-332 FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report on Initial 24 Month Outcomes
- Author
-
Abizaid, Alexandre, primary, Didier, Carrie, additional, Frey, Norbert, additional, Lutz, Matthias, additional, Weber-Albers, Joachim, additional, Dudek, Darius, additional, Chevalier, Bernard, additional, Lansky, Alexandra, additional, and Anderson, Jeffrey, additional
- Published
- 2017
- Full Text
- View/download PDF
6. TWO-YEAR RESULTS OF THE PLATINUM RANDOMIZED TRIAL COMPARING PLATINUM CHROMIUM PROMUS ELEMENT AND COBALT CHROMIUM PROMUS/XIENCE V EVEROLIMUS-ELUTING STENTS IN DE NOVO CORONARY ARTERY LESIONS
- Author
-
Didier Carrie, Dominic Allocco, Helge Möllmann, Jack Hall, Keith Dawkins, Ian T Meredith, Keith Oldroyd, Alain Bouchard, Paul S. Teirstein, and Gregg W. Stone
- Subjects
medicine.medical_specialty ,business.industry ,Everolimus eluting stent ,chemistry.chemical_element ,law.invention ,Surgery ,Chromium ,medicine.anatomical_structure ,chemistry ,Randomized controlled trial ,law ,Medicine ,Cardiology and Cardiovascular Medicine ,business ,Platinum ,Nuclear medicine ,Cobalt ,Artery - Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.